Breast Replacement

Used in baked goods (breads, cakes and cake mixes, cookies, crackers, snacks), pasta products, dairy-type products (beverage powders, coffee whiteners, whipped toppings), infant formulas, milk replacers for young animals, emulsified and coarsely ground meat items, meat analogues, hams, poultry breasts, dietary food items, and soup mixes and gravies. 

Uses of lactose production by appHcation include baby and infant formulations (30%), human food (30%), pharmaceuticals (25%), and fermentation and animal feed (15%) (39). It is used as a diluent in tablets and capsules to correct the balance between carbohydrate and proteins in cow-milk-based breast milk replacers, and to increase osmotic property or viscosity without adding excessive sweetness. It has also been used as a carrier for flavorings. 

There is much interest in the possible hormonal effects of phytoestrogens in both men and women. The majority of studies conducted in women have examined the ability of phytoestrogens to alleviate menopausal symptoms. Whilst hormone replacement therapy is recommended for women experiencing menopausal symptoms, there remains some uncertainty as to whether HRT can increase the risk of breast cancer. As a result of these concerns, investigations into natural alternatives such as phytoestrogens have received considerable attention. 

Congenital hypothyroidism is still seen in the United States, and all newborns in the United States undergo screening with a TSH level. As soon as the hypothyroid state is identified, the newborn should receive the full LT4 replacement dose. The replacement dose of LT4 in children is age-dependent. In newborns, the usual dose is 10 to 17 mcg/kg per day. LT4 tablets may be crushed and mixed with breast milk or formula. Serum FT4 levels (target 1.6-2.2 ng/dL or 20.59-28.31 pmol/L) are used for dose titration in infants because the TSH level may not respond to treatment as it does in older children and adults. By 6 months of age, the required dose is reduced to 5 to 7 mcg/kg per day, and from ages 1 to 10 years, the dose is 3 to 6 mcg/kg per day. After age 12, adult doses can be given. 

Long-term use of hormone-replacement therapy and concurrent use of progestins appear to contribute to breast cancer risk.7 The use of postmenopausal estrogen-replacement therapy in women with a history of breast cancer generally is considered contraindicated. However, most experts believe that the safety and benefits of low-dose oral contraceptives currently outweigh the potential risks and that changes in the prescribing practice for the use of oral contraceptives are not warranted. Oral contraceptives are known to reduce the risk of ovarian cancer by about 40% and the risk of endometrial cancer by about 60%. 

Combining both heating and nonheating protocols employed in a sequential order were evaluated, but without any advantage (Fig. 3.4). RT-PCR was performed by standard methods, RNA extracted from fresh MDA cells and human tissue of breast cancer with known tested genes was used as positive control, and pure water was used to replace template (cDNA) as negative control for every experiment of PCR. To assure the accuracy of PCR tests, all reactions were performed in triplicate. 

A 50- year-old female had a radical mastectomy three years ago for hormone-dependent breast adenocarcinoma. She is now complaining of shortness of breath, and chest X-ray shows diffuse lung metastases. As part of her therapeutic regimen, she is given intramuscular hormone replacement therapy (1IRT). 

In a reanalysis of 51 studies, less than 5 years of therapy with combined estrogen and progestogen was associated with a 15% increase in risk for breast cancer, and the risk increased with greater duration of treatment. Five years after discontinuation of hormone replacement therapy, the risk of breast cancer was no longer increased. 

Colditz GA (1998) Relationship between estrogen levels, use of replacement theraphy and breast cancer. J Natl Cancer Inst 90 814... 

Diamanti-Kandarakis E, Sykiotis GP, Papavassiliou AG (2003) Selective modulation of postmenopausal women cutting the Gordian knot of hormone replacement therapy with breast carcinoma. Cancer 97 12... 

Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 419-427... 

Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350 1047-1059... 

Holli K, Isola J, Cuzick J (1997) Hormone replacement therapy and biological aggressiveness of breast cancer. Lancet 350 1704-1705... 

Santen RJ, Pinkerton J, McCartney C (2001) Clinical review 121 Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 86(l) 16-23... 

Hormone therapy has proven highly effective in controlling the menopausal syndrome, especially severe hot flushes (MacLennan et al. 2004), even at doses significantly lower than those used until now (Speroff et al. 2000 Utian et al. 2001). Women s Health Initiative studies found that hormone replacement therapy, when administered as a primary prevention intervention for CVD in older women, increases the risk of heart disease and breast cancer. Even if a protective effect on fracture and colon cancer was observed, the risk-benefit ratio led to a recommendation of this treatment only for the short-term relief of menopausal symptoms (Rossouw et al. 2002 Anderson et al. 2004). The role of early administration of ovarian hormones to young postmenopausal women in the prevention of cardiovascular disease or late dementia remains... 

Besides contraception, the uses of estrogens can largely be put into three main groups the management of the menopausal and postmenopausal syndrome (its widest use) physiological replacement therapy in deficiency states and the treatment of prostatic cancer and of breast cancer in postmenopausal women. 

---